Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Nordea Investment Management AB

Nordea Investment Management AB boosted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 441.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 125,363 shares of the company's stock after buying an additional 102,226 shares during the quarter. Nordea Investment Management AB's holdings in Dr. Reddy's Laboratories were worth $1,992,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. World Investment Advisors LLC acquired a new position in Dr. Reddy's Laboratories during the third quarter worth about $3,459,000. Frank Rimerman Advisors LLC acquired a new position in Dr. Reddy's Laboratories during the second quarter worth about $2,633,000. Geode Capital Management LLC grew its position in Dr. Reddy's Laboratories by 109.3% during the third quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock worth $1,053,000 after buying an additional 6,920 shares during the period. GAMMA Investing LLC grew its position in Dr. Reddy's Laboratories by 369.9% during the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company's stock worth $107,000 after buying an additional 5,352 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Dr. Reddy's Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock worth $76,455,000 after buying an additional 114,294 shares during the period. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RDY has been the topic of several research reports. Barclays lowered their price target on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. Finally, StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th.

Dr. Reddy's Laboratories Price Performance

Shares of RDY stock traded down $0.40 during trading hours on Friday, hitting $15.41. The company's stock had a trading volume of 3,905,414 shares, compared to its average volume of 1,397,270. Dr. Reddy's Laboratories Limited has a twelve month low of $13.43 and a twelve month high of $16.89. The business has a fifty day moving average of $14.84 and a 200-day moving average of $15.55. The stock has a market cap of $12.86 billion, a price-to-earnings ratio of 24.62 and a beta of 0.53. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.